Skip to main navigation Skip to search Skip to main content

Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma

  • Daphne N. Dorst
  • , Esther M.M. Smeets
  • , Christian Klein
  • , Cathelijne Frielink
  • , Daan Geijs
  • , Marija Trajkovic-Arsic
  • , Phyllis F.Y. Cheung
  • , Martijn W.J. Stommel
  • , Martin Gotthardt
  • , Jens T. Siveke
  • , Erik H.J.G. Aarntzen
  • , Sanne A.M. van Lith
  • Amalia Children's Hospital
  • F. Hoffmann-La Roche Ltd.
  • University Hospital of Essen
  • German Cancer Research Center

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of 111In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (CKP). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In CKP mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC.

Original languageEnglish
Pages (from-to)4319-4330
Number of pages12
JournalMolecular Pharmaceutics
Volume20
Issue number8
DOIs
StatePublished - 7 Aug 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cancer-associated fibroblast (CAF)
  • fibroblast activation protein (FAP)
  • pancreatic ductal adenocarcinoma (PDAC)
  • syngeneic models
  • targeted photodynamic therapy (tPDT)

Fingerprint

Dive into the research topics of 'Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma'. Together they form a unique fingerprint.

Cite this